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Abstract 
Non-alcoholic fatty liver disease (NAFLD) prevalence has reached epidemic proportions and the 
severe type, non-alcoholic steatohepatitis (NASH) is predicted to become the leading cause of 
liver transplant over the next two decades. The growing prevalence requires primary care (PC) 
providers to be adept at recognition and management. However, PC providers experience 
significant knowledge gaps which can result in delayed access to intervention that could improve 
outcomes. In response, the online NAFLD toolkit was developed, implemented, and evaluated 
using the Knowledge to Action framework in an effort to improve knowledge gaps and support 
evidenced-based practice among PC nurse practitioners (NPs) in a midwestern state. The success 
of the toolkit was evaluated by administering the NAFLD survey for general practitioners in a 
pre-post evaluation design. Responses (n=11) were compared for statistical significance using 
the Wilcoxin signed-rank test for matched pairs and showed improvement in overall knowledge 
score (p=0.011), perceived comfort scores (p=0.07), and intention to use the non-alcoholic fatty 
liver disease fibrosis score (NAFLD-FS) for patient monitoring and weight loss for management 
(p=0.008).  The results of this project demonstrate successful implementation of a toolkit to 
support evidenced-based practice and support expanded use of the toolkit. Continued evaluation 
on a larger scale is needed.  
Keywords: NAFLD-FS, NAFLD, NASH, toolkit, evidenced-based practice 
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In 1980, a team from Mayo Clinic described what was at the time a new and previously 
unknown disease (Ludwig, Viggiano, McGill, & Oh, 1980).  This chronic disease, non-alcoholic 
fatty liver disease (NAFLD), has reached epidemic proportions (Younossi et al., 2016), yet 
primary care providers (PCP) report knowledge gaps regarding the disease and its management. 
The purpose of this paper is to describe an evidenced-based practice (EBP) project that used a 
toolkit to increase PC Nurse Practitioner (NP) awareness and knowledge of NAFLD.  This paper 
will define NAFLD and toolkits, describe the diagnosis and management of NAFLD, and 
describe the use of toolkits in quality improvement. It will also review the literature surrounding 
these concepts and knowledge gaps regarding NAFLD. Next, this paper will present the process 
for implementation and evaluation of the toolkit. Finally, conclusions from the project and 
implications for future scholarship will be discussed.   
Background  
NAFLD is a concerning epidemic. Nationally, it affects one third of adults and results in 
103 billion dollars in healthcare costs annually. Its prevalence is rapidly increasing while 
infectious and alcoholic liver disease prevalence remains stable (Ruhl & Everhart, 2015; 
Younossi et al., 2011).  For example, between 1998 and 2012, National Health and Nutrition 
Examination Survey data showed a 68% increase of NAFLD prevalence (Ruhl & Everhart, 
2015). NAFLD is expected to become the leading reason for liver transplantation within the next 
two decades (Zezos & Renner, 2015). The global impact of NAFLD is similar to that of the 
United States (Pereira, Salsamendi, & Casillas, 2015) 
NAFLD is characterized by excess fat storage, called steatosis, in the liver.  There are 
two categories of NAFLD: NAFL and NASH.  NAFL is defined by steatosis that occurs without 
inflammation whereas NASH is defined by steatosis, inflammation, and sometimes fibrosis 
                                                                                             7 
 
(Dharel & Fuchs, 2014). Fibrosis is graded using a four-point Kleiner scale as defined by liver 
biopsy results. One indicates mild fibrosis, two moderate fibrosis, and three severe fibrosis. A 
score of zero indicates no fibrosis; four identifies cirrhosis (Kleiner et al., 2005).   
NASH is the more concerning form of NAFLD due to its severity. It occurs in an 
estimated 20% of patients with NAFLD (Spengler & Loomba, 2015). While the NAFL subset of 
NAFLD usually follows a benign course, NASH can progress along a continuum of severe liver 
fibrosis, cirrhosis, and liver failure. Hepatocellular carcinoma (HCC) is also possible. (Chalasani 
et al., 2017). Patients with NASH progress to severe fibrosis twice as fast as patients with NAFL 
and it is estimated that up to 20% of patients with NASH can develop cirrhosis and HCC (Nones 
et al., 2017; Stal, 2015). 
NAFLD is considered the liver manifestation of metabolic syndrome. Likewise, rising 
incidence of two components of metabolic syndrome, obesity and impaired glucose tolerance 
(specifically, diabetes), are largely responsible for the increasing prevalence of NAFLD 
(Balesteri, 2014; Chalasani et al., 2017, Charlton et al., 2011; Lazo et al. 2013).  Obese patients 
have the highest prevalence of NAFLD, with rates close to 90% (Chalasani et al., 2017), and are 
more at risk of NAFLD than their normal weight counterparts (p=0.005) (Portillo-Sanchez et al., 
2015). Because obesity and diabetes rates continue to climb despite being key targets of Healthy 
People 2020, NAFLD will continue to be a pressing national health concern  (Department of 
Health and Human Services, 2014; Trust for America’s Health & Robert Wood Johnson 
Foundation, 2016).  
Improving care of the patient with NAFLD presents many challenges. One challenge is 
improving PCPs ability to recognize the disease in its early stages early. Mild or absent 
symptoms make it challenging to recognize NAFLD and this is compounded by knowledge gaps 
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and limited training in the disease (Blais et al., 2015; Dharel & Fuchs, 2014; Polanco-Briceno, 
Glass, Stuntz, & Caze, 2016). Early identification by PCPs is especially important since NASH- 
induced cirrhosis confers an increased risk of HCC and liver failure and these complications 
have better prognosis with early identification.  Unfortunately, PCPs often overlook patients at 
this increased risk (Angulo et al. 2007; Stal, 2015).  Therefore, as the epidemic of NAFLD 
continues to grow, PCPs need education to recognize and manage patients with NAFLD (de 
Silva & Dassanayake, 2009)  
The purpose of this evidenced-based project is, therefore, to design and evaluate an 
online toolkit for PCPs, specifically, PCNPs, to improve knowledge gaps regarding NAFLD. A 
toolkit is “a collection of related information, resources, or tools that together can guide users to 
develop a plan or organize efforts to follow evidence-based recommendations or meet evidence-
based specific practice standards” (Agency for Healthcare Research and Quality [AHRQ], 2016, 
para 1). Toolkits can help speed the delivery of research into practice and are provided in two 
primary formats: written and web/electronic-based (Barac, Stein, Bruce & Barwick, 2016; Davis 
et al., 2017). Toolkits have been used to address provider knowledge gaps in a wide range of 
conditions such as autism (Bellando, Fussell, & Lopez, 2016), hypertension (Savarimuthi et al., 
2013), and dementia (Graham et al., 2017). In 2016, the AHRQ developed guidance for and a 
checklist of best practices when designing toolkits.  
 This project was conducted in cooperation with the Association of Missouri Nurse 
Practitioners (AMNP). AMNP has over 500 active nurse practitioners (NP) and NP student 
members.  Approximately 75% practice in primary care.  AMNP was approached as a partner 
since the project matches the organization’s purposes of  promoting “excellence in practice, 
education, and research” and assisting professional growth and continuing education of nurse 
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practitioners (AMNP, 2017, para 1).  An  official letter of support for this project can be found in 
Appendix A. 
Overview of NAFLD 
NAFLD pathophysiology 
 Pathophysiology of NAFLD has been briefly reviewed in the introduction of this paper, 
introducing the concept that in some patients, liver steatosis progresses onto inflammation, 
fibrosis, and eventually, liver cirrhosis.  It typically can take years to make this transition, 
averaging 7.7 years between progression of each fibrosis stage (Calzadilla-Bertot & Adams, 
2016). Experts are still unclear how to predict which patients will develop NASH over remaining 
in the benign NAFL category and while the pathophysiology of NAFLD is known to be a 
predominantly inflammatory process, it is also complex and still incompletely understood.  The 
most recognized pathogenic processes inducing the inflammatory mechanisms include poor diet, 
high caloric intake, high fructose/sucrose intake, and changes in intestinal flora (Byrne & 
Targher, 2015).  Genetics is also  a major contributor, with the patatin-like phospholipase 
domain containing (PNPLA3) gene mutation being the most recognized genetic variant (Eslam, 
Valenti, & Romeo, 2017). NAFLD is also associated with several other chronic conditions 
including cardiovascular disease (CVD) and chronic kidney disease.  In fact, even though 
persons with NASH have an increased risk of liver-related mortality compared to non-NASH 
counterparts, CVD, not liver failure, is the leading cause of mortality in individuals with NAFLD 
(Byrne & Targher, 2015).   
NAFLD Diagnosis  
Lab work. NAFLD is rarely suspected until after laboratory testing reveals an elevated 
aspartate aminotransferase (AST) or alanine aminotransferase (ALT). Though the differential 
                                                                                             10 
 
diagnosis of patients with elevated AST/ALT can be vast, recent literature, including a 
systematic review, shows NAFLD is the most common reason for elevated AST/ALT; Alcoholic 
liver disease and viral hepatitis follow as the second and third (Lee, Kim, & Poterucha, 2012; 
Radcke, Dillon, & Murray, 2015). Since NAFLD is considered the liver manifestation of 
metabolic syndrome, clinicians can be relatively certain that patients with obesity or glucose 
intolerance have NAFLD. However, it is still important to consider other causes of elevated 
AST/ALT as obesity and glucose intolerance does not negate the chance of concurrent viral 
hepatitis infection or alcoholic liver disease (Younissi et al., 2004). Moreover, many patients 
with obesity or metabolic syndrome were born during years that meet the hepatitis C screening 
recommendation set by the Centers for Disease Control (Smith et al., 2012).  
When patients present with elevated AST/ALT, the literature is not in complete 
agreement on exact steps and end points in the work-up.  However, recurrent themes in the 
literature were noted as follows.  First, patients should be screened for viral hepatitis. Next, 
patients should have screening for alcohol misuse. One available tool to exclude alcohol misuse 
is the AUDIT-C (appendix B). It has been used in studies of NAFLD to rule out alcoholic abuse 
as the cause of elevated ALT/AST (Blais et al., 2015).  After alcohol misuse is excluded as a 
potential factor, medication induced liver injury, autoimmune hepatitis, and hemochromatosis 
are other, less common, possible diagnoses that should be considered. Finally, liver ultrasound 
should be conducted to evaluate for steatosis. A 2017 clinical guideline agrees with these themes 
(Kwo, Cohen, & Lim, 2017) and the literature findings and guidelines were incorporated into an 
algorithm (appendix C) developed for this project toolkit.   
           Two sources of contention in the literature regarding NAFLD diagnosis are screening and 
evaluation for NAFLD in the presence of normal ALT/AST.  Screening for NAFLD can either 
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be done with ALT/AST, ultrasound or non-invasive calculations such as the NAFLD-FS. 
However, current United States NAFLD practice guidelines do not recommended screening in 
any form, even in patients with diabetes and metabolic syndrome (Chalasani et al., 2017).  This 
argument is partly due to lack of proven cost-effectiveness (Corey et al., 2016).  Rather than 
screening, experts recommend increased “vigilance” in monitoring for NAFLD, though little 
explanation is given. (Wong & Chalasani, 2016).  Other literature counters this opinion stating 
there is an overreliance on normal ALT/AST to exclude NAFLD (Ratziu et al., 2012; Rinella, 
2015). Additionally, the European Association for the Study of the Liver (EASL) guidelines call 
for screening with ultrasound or ALT/AST in those with metabolic syndrome, diabetes, and or 
obesity (Nascimbeni et al., 2013).  It is likely that the recommendations against screening will 
change as newer research and treatments for NASH become available resulting in screening 
becoming more cost effective (Corey et al., 2016).   
Liver biopsy. Liver biopsy has traditionally been the gold standard to identify NASH, 
the severe form of NAFLD (Chalasani et al., 2017; Spengler & Loomba, 2015), but multiple 
concerns over liver biopsy have driven the development of non-invasive diagnostic options like 
the NAFLD-FS. The vast prevalence of NAFLD makes it impossible to perform a liver biopsy 
on every patient with NAFLD and identify fibrosis in this manner (Dietrich & Hellerbrand, 
2014). Further, liver biopsies are not without mortality, morbidity and expense concerns and are 
prone to sampling errors (Angulo et al., 2007; Chalasani et al., 2017)). Moreover, the accuracy of 
liver biopsy, measured by the area under receiver operating characteristic (AUROC), is only as 
high as 0.85 and many noninvasive options perform similarly or better (Musso et al., 2011).  
Noninvasive diagnosis. Clinicians usually suspect NAFLD based on presence of 
metabolic syndrome and persistently elevated ALT or AST and/or steatosis detected on liver 
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ultrasound. The next step is then to determine whether NAFL or NASH is present. Traditionally, 
liver biopsy was used for diagnosis, but diagnosis is now being done with noninvasive diagnostic 
options. One challenge in diagnosing NASH with non-invasive diagnostic methods, is that unlike 
liver biopsy, the non-diagnostic methods cannot differentiate NAFL from NASH; they can only 
differentiate NASH with advanced fibrosis (Kleiner score three or higher) from more benign 
forms of NAFLD (NAFL or NASH with mild to moderate fibrosis). However, this concern is 
mitigated by the fact that patients with NASH and mild or moderate fibrosis can be managed in 
primary care and need not be managed by hepatology until severe fibrosis or cirrhosis is 
suspected (Chalasani et al., 2013; McPherson et al., 2013; Tapper et al., 2016).   
The NAFLD-FS is the most popular non-invasive diagnostic option for detecting 
advanced fibrosis in NASH. NAFLD-FS is calculated using age, AST, ALT, platelet level, 
albumin level, presence of hyperglycemia, and Body Mass Index (BMI): all factors inversely 
related to severity of liver fibrosis in NASH (Chalasani et al., 2017). Although there are 12 other 
validated non-invasive diagnostic options, NAFLD-FS is the best studied, easily available in 
primary care, and most preferred by clinical experts (Chalasani et al, 2017). Therefore, it was 
selected as a tool in this project toolkit.  Angulo et al. (2007) performed the seminal study that 
defined the NAFLD-FS for diagnosing advanced fibrosis in NASH.  Using a cross-sectional 
design, the researchers sought to define a noninvasive scoring system that would allow 
stratification of NAFLD patients into two groups: those with and without advanced fibrosis.   
Angulo et al. identified the variables that were independently associated with advanced fibrosis 
(Kleiner scale three or four on liver biopsy) and created a calculation that was titled the NAFLD-
FS. The NAFLD-FS was designed with three primary ranges. Scores below -1.455 are used to 
rule out severe liver fibrosis.  Scores >0.676 presented concern for severe fibrosis and scores of -
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1.455 to 0.676 were considered indeterminate and did not provide valuable information.  
AUROC was calculated at .82 and the authors concluded that the NAFLD-FS would have 
prevented the 60 percent of patients with scores below -1.455 from needing liver biopsy.    
Since this seminal study, the NAFLD-FS has mostly been studied in specialty settings 
(Cichoz-Lach et al., 2012,  McPherson et al., 2010, Lykiardopoulos et al., 2013, McPherson et al. 
2013, Petta et al., 2013, & Ruffillo et al., 2011), but has been used in various other settings such 
as diabetic clinics (Armstrong et al., 2014), bariatric clinics (Pimentel et al., 2010) and primary 
care clinics (Armstrong et al., 2012 & Blais et al. 2015). Two recent meta-analyses demonstrate 
continued support for the NAFLD-FS (Musso et al., 2011; Xiao et al., 2017). Musso et al. 
compared noninvasive diagnosis of NASH induced liver fibrosis to liver biopsy and noted the 
NAFLD-FS performed at an AUROC of .85 (.80–.93).  Performance of the NAFLD-FS in Xiao 
et al. (2017) also found an AUROC of .85.    
Liver stiffness measurement (LSM), also known as elastography, is also being used in the 
non-invasive diagnosis of NAFLD and strengthens noninvasive diagnosis (Musso et a., 2011).  
LSM can be assessed through magnetic resonance imaging or ultrasound, but because of  a more 
favorable cost profile, ultrasound is the more popular method. Available under the name brand 
Fibroscan, ultrasound LSM, was approved by the FDA in 2013 (Echosens, 2017). One drawback 
to Fibroscan is its limited availability, but access to the method is quickly expanding. Other 
drawbacks to Fibroscan include reduced accuracy in obese patients; however, this has been 
improved by development of an extra large (XL) probe. In a recent meta analysis (Tsochostakas 
et al., 2011), sensitivity and specificity of Fibroscan  was 0.79 (95% CI 0.74–0.82) and 0.78 
(95% CI 0.72–0.83) for moderate fibrosis and 0.83 (95% CI 0.79–0.86) and 0.89 (95% CI 0.87–
0.91) for cirrhosis.  
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In addition to non-invasive scoring systems and transient elastography, there are several 
other non-invasive diagnostic options on the horizon. Discussion is beyond the scope of this 
paper, though one of the most promising is cytokeratin 18 (CK-18) (Kaswala, Lai, & Afdhal, 
2016). CK-18 is still considered investigational, however, and not yet recommended by clinical 
guidelines (Chalasani et al., 2017). 
NAFLD Management 
Currently, there are no Federal Drug Administration (FDA) approved methods to 
specifically manage NAFLD. While FDA approved medications focused on treating related 
comorbidities such as obesity or diabetes are available, in the direct management of NAFL and 
NASH, lifestyle modifications are the predominate treatment modality. Caloric restriction, in the 
range of 500-750 kcal/day, and exercise, with a goal of 150 minutes per week, are the current 
recommendations (Younissi et al.,  2017; Hannah & Harrison, 2016; Kenneally, Sier, & Moore, 
2016).  Strength training in addition to or as part of an exercise regimen can also be helpful 
(Hannah & Harrison).  While the Mediterranean diet is a proven method for caloric restrictions 
in other chronic conditions and has been proposed for NAFLD (Trovato et al., 2015), patients 
should be encouraged to tailor caloric restrictions to personal preferences or use a combination of 
modalities since the focus should be more on amount of weight loss (Kenneally, Sier, & Moore, 
2016). A weight loss of seven to ten percent of body weight results in regression of fibrosis in 
NASH, while even as little as five percent weight loss can stabilize NASH.  However, 
maintenance of weight loss and improved lifestyle is challenging with less than half being able to 
maintain weight loss in the long term (Chalasani et al., 2017; Glass et al., 2015).   
Because achieving weight loss and improved lifestyle is challenging, clinicians should 
consider using motivational interviewing (MI) with NAFLD patients. A mainstay of practice for 
                                                                                             15 
 
problems like substance abuse, MI is useful in helping patients achieve weight loss and other 
lifestyle changes (Barnes and Ivezaj, 2015; Hardcastle et al., 2013) and has been specifically 
proposed for NAFLD (Centis et al., 2012; Marchesini, Petta, & Dalle Grave, 2016; Stewart et al., 
2015).   
Bariatric surgery for weight loss is also effective in inducing and maintaining therapeutic 
weight loss in patients with NAFLD. More invasive surgical interventions (malabsorptive over 
restrictive procedures) produce better outcomes in terms of long-term maintenance of weight loss 
(Øvrebø, Strømmen, Kulseng, & Martins, 2017; Scheen et al., 2005).    
Pharmaceutical treatments for NAFLD are of intense interest. Many trials are currently 
being conducted for novel treatments.  As previously stated there are no FDA approved 
treatments. However, guidelines do offer a few recommendations for pharmaceutical treatment 
(Chalasani et al., 2017). One treatment is vitamin E.  However, vitamin E is only recommended 
in non-diabetic patients, therefore missing a large proportion of patients with NAFLD.  
Guidelines also discuss treating NASH with thiazolidinediones and research has found 
pioglitazone improves liver histology, though weight gain side effects and contraindications in 
cardiac disease limit its use.  Preliminary research on Glucagon-like-peptide (GLP-1) agonists in 
NAFLD is promising, but there is not enough research to recommended their use at this time.  
Probiotics and the role of intestinal health are another focus of current research, but guidelines 
await further research before offering recommendations (Lavekar et al., 2017). 
Literature Review 
As this project aims to produce a useful toolkit regarding NAFLD to deliver the 
aforementioned content for primary care providers, the literature describing NAFLD knowledge 
gaps of PCPs and how to improve them was evaluated. Additionally, literature was reviewed for 
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evidence of toolkit effectiveness in addressing knowledge gaps. After describing the 
methodology for this literature review, this section will first examine the literature exploring the 
knowledge gaps regarding NAFLD that sets the stage for the rationale of this project.   Next, the 
literature regarding best practice in toolkit design and toolkit effectiveness in clinical practice is 
reviewed.   
Methods 
 This literature review followed a standard review method. A research literature search 
map guided by the PICO question was used: Does the use of a NAFLD online toolkit (I), 
improve Primary Care Providers (P) awareness of NAFLD (O)?    The Cumulative Index to 
Nursing and Allied Health Literature, Google Scholar, and PubMed search engines were queried 
using the terms  “NAFLD”, “NASH”, “diagnosis”, “treatment” and “awareness” and searches 
were conducted with both these abbreviations and the corresponding full written phrase.  Other 
keywords used were “toolkits”, “knowledge” and “primary care”.  Bibliographies from retrieved 
articles were used to look for other original research.   Inclusion criteria limited studies to adult 
populations within the United States or Europe.  Research in those under 18 years old was 
excluded.  Grey literature was explored and systemic reviews on the topic were also reviewed. 
Because there were no articles discussing toolkits with NAFLD, literature exploring the use of 
toolkits regarding other diagnoses was performed as well as review of other NAFLD education 
programs. Initially, the literature search was limited to seven years, but even though there was 
much literature describing toolkits, there was limited literature on research regarding toolkit 
effectiveness.  Therefore, the literature review for toolkit effectiveness was expanded as far back 
as 14 years. 
NAFLD Knowledge gap 
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 Defining the knowledge gap.  
Health care providers. Several studies have identified a PCP knowledge gap regarding 
NAFLD.  Three of these studies have been performed in the United States. Wieland et al. (2013) 
conducted a survey among 246 non-hepatology health care providers and was the only study to 
include NPs in their sample, though the sample was primarily physicians (92%). Only 31 % of 
the sample felt NAFLD was a clinically important issue while 83 % percent identified a need for 
education.  Polanco-Briceno et al. (2016) used a nationwide online survey of physicians to 
analyze attitudes regarding NAFLD; one-half of the 302 physician only sample was primary care 
physicians (PCP). Half of these PCPs were unfamiliar with the differences between NAFL and 
NASH, yet they were managing patients with both diseases. Said et al. (2013) found similar 
findings in their survey of 119 physician only PCPs in Wisconsin. Eighty four percent of 
providers underestimated the prevalence of NAFLD even in obese and diabetic individuals. 
Fifty-eight percent reported a lack of confidence with disease treatment and reported this was a 
barrier to providing care for NAFLD patients.  All three studies concluded a strong need for 
education among PCPs in the United States. A strength of the studies are the generalizability to 
the United States PCP population. A weakness is the low to absent representation of NP 
providers. 
Five other studies looked at attitudes of providers outside the United States and found a 
similar impact of knowledge gaps.  These studies included physician only samples. Two of these 
studies, focused on knowledge gaps in Australia among non-hepatology providers (Bergqvist et 
al., 2013 & Patel et al., 2017). While Bergqvist et al. (2013) studied hospitalists, Patel et al. 
(2017) studied PCPs.  Both studies found a significant knowledge gap regarding the prevalence 
of NAFLD.  Bergqvist et al. found that 75% of the 100 Australian hospitalists in the study 
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underestimated the prevalence of NAFLD while Patel et al. (2017) noted that among 108 PCPs, 
58 % underestimated the prevalence of NAFLD.  Patel et al. also found that nearly half of their 
sample erroneously thought that liver enzymes are sensitive enough to rule out NAFLD or were 
unsure of the role of liver enzymes in diagnosis. Additionally, the majority of the clinicians only 
used liver enzymes or abdominal ultrasound to diagnose NAFLD and failed to use recommended 
tools in guidelines such as the NAFLD-FS. Thirty one percent of the sample in Patel et al. 
volunteered that the survey made them realize they had an unrecognized knowledge gap. Both 
studies concluded a need for training of health care providers regarding NAFLD. 
Ratziu et al. (2012) surveyed 352 French gastroenterologists to determine knowledge 
gaps in France. Only 22% of the sample would pursue a NAFLD diagnosis if AST/ALT were 
normal even if patients had metabolic risk factors or obesity.  This finding is similar to 
previously discussed studies and important, given that AST/ALT has low sensitivity for ruling 
out NAFLD and specifically NASH. Ratziu et al. specifically highlighted a lack of collaboration 
among specialists and primary care providers in their study.  
In a survey of 64 PCPs in the Netherlands, van Asten et al. (2017) noted 84% of the 
surveyed sample reported a need for more education and only one of the providers reported 
consulting clinical guidelines for NAFLD.  Of concern, 24 % of those surveyed did not know the 
NAFLD acronym and 53% were unaware of the NASH acronym. Van Asten (2017) also noted a 
lack of collaboration stating that hepatology and primary care providers should work closely 
together to reduce the amount of undiagnosed NAFLD and that together they should “develop, 
validate, and communicate noninvasive tools and algorithms for the detection, referral, and 
(parallel) follow up” of patients (p. 1078). 
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Avery et al. (2017) used qualitative research methods to explore NAFLD knowledge and 
attitudes in the United Kingdom. The sample included 21 healthcare providers in hepatology, 
gastroenterology, diabetology, and primary care.  A unique aspect of this study was that it also 
included 11 patients in the sample to provide this perspective. Findings included a need for 
clinical education for providers and patient education development.  Several of the providers 
responded that coaching on motivational interviewing techniques would be helpful since lifestyle 
changes are the cornerstone of current management.  Hepatology specialists in this sample did 
notice improvement in referring providers use of guidelines and scoring techniques such as the 
NAFLD-FS prior to referral, but also noted a general lack of comfort from PCPs who often 
requested referral to confirm treatment plan.  Concerning findings in this study were the patient 
stated lack of education and support given to them by health care providers. Surprisingly, one 
patient was told to “google” NAFLD by her PCP, rather than the PCP providing her education.  
A weakness of this study was the lack of detailed description of the sample (physicians versus 
non-physician providers). A strength of the study is that it the only known qualitative study to 
illustrate knowledge gaps of NAFLD. 
In summary, the literature above has illustrated a knowledge gap among mostly physician 
PCPs. It is unclear whether this knowledge gap extends to PCNPs since NPs were 
underrepresented in the study samples. The nature of this project design allowed an opportunity 
to address the underrepresentation of PCNPs. A total of 20 PCNPs completed the pre-survey 
portion of the project, but only eleven went on to view the toolkit and complete the post-survey. 
However, the 20 completing the pre-survey were compared in a separate analysis (phase one, see 
appendices @) and added data on PCNP NAFLD knowledge gaps to the general research 
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community.  Further discussion of the findings are included in the data analysis and discussion 
sections of this paper.    
Public Awareness. Recent studies have also demonstrated a NAFLD knowledge gap 
among the general public.  Ghevariya et al (2014) interviewed 4000 patients in Brooklyn and 
found only sixteen percent knew the causes of NAFLD and 95% failed to realize that fatty liver 
was a problem.  Further, 84 % of the patients were not aware of conditions that can cause 
NAFLD or cirrhosis. Wieland et al. (2015) conducted a survey of 302 patients in an United 
States endocrinology clinic and found that of patients at risk for NAFLD due to obesity or 
diabetes, only 18 % were aware of NAFLD.  Another study by Goh et al. (2016) showed that 
75% of patients with one or more metabolic risk factors did not believe they were at risk for 
NAFLD.   However, despite this lack of awareness, patients desire education. For example, 75 % 
of surveyed patients in Wieland et al. were interested in education.  Unfortunately, a previously 
discussed study in the United Kingdom noted that health care providers do a poor job of 
educating patients (Avery et al., 2017). Therefore, for this project several patient education tools 
were developed and provided as part of the toolkit. 
 Reasons for knowledge gaps. The literature was briefly explored to examine reasons 
that there might be a knowledge gap and lack of clinical guideline awareness and 
implementation. Literature specific to NAFLD guidelines and reasons for NAFLD knowledge 
gaps were not identified.  However, several resources have described reasons for knowledge 
gaps and problems with adherence to clinical guidelines in general. In a landmark paper 
examining why physicians don’t use clinical practice guidelines, Cabana et al. (1999) 
investigated 76 articles and found lack of awareness and familiarity with guidelines and recent 
research were among the top reasons.  Confusion regarding guidelines and feeling guidelines 
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were cumbersome were also important factors influencing their use.   Keiffer (2015) specifically 
examined the same themes among 17 non-physician providers in the United States and found the 
strongest reason was an inability to stay updated with the constantly evolving guidelines in ones 
field as well as lack of awareness of their availability. 
Toolkits to address knowledge gaps. 
The aforementioned literature demonstrates knowledge gaps regarding NAFLD and 
possible reasons for the gaps. Toolkits that provide education and resources for providers are one 
solution to this problem. While toolkits are wide spread in use and many examples are found, 
they are not always evaluated for effectiveness. The following literature review sought to 
examine evidence-based design of toolkits for use in NAFLD. During the literature review, only 
one research article on a NAFLD educational event targeting knowledge gaps was found, but no 
literature regarding a toolkit for NAFLD was available. Therefore, this literature review will 
discuss the sole article on addressing NAFLD knowledge gaps and then discuss literature 
regarding qualities that make an effective toolkit.  Next,  a review of success and failure of 
toolkits in other health problems outside of NAFLD is discussed.  
Addressing NAFLD knowledge gaps. Only one study has tried to target provider lack of 
knowledge regarding NAFLD.  Grattagliano et al. (2008) studied the Steatostop project, a full 
day teaching workshop in Italy and found positive results. An unique aspect of this study was 
that it collected data on referral and other practice patterns for a combined 212 NAFLD patients 
cared for by PCP participants for the  two months preceding the educational event. It also 
surveyed the 56 PCP participants six months before and directly after the educational event and 
found statistically significant improvement in all knowledge areas which included screening for 
NAFLD, referral for liver biopsy, and management.  The study noted that knowledge prior to the 
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education event was “barely adequate” (p. 391).  Patient data showed the most common errors in 
NAFLD care were the failure to exclude alcohol use (only excluded in 7 out of 212 patients) and 
a failure to consider NAFLD in patients with both elevated ALT/AST and obesity/diabetes.  
After the educational event, 40% of the PCPs reported they would  better investigate for 
NAFLD. This study’s weaknesses include the lack of validation of the questionnaire used to 
query PCPs and failing to assess for long-term knowledge gains by only surveying participants 
directly after the educational event.  The research is also over 10 years old, which is another 
weakness.  However, its strength is that this study is the only one to address NAFLD knowledge 
gaps among PCPs. 
Components of a good clinical toolkit. In order to develop a clinically useful toolkit, it was 
important to review the available research for effective design.  A recent qualitative study 
interviewed 96 primary care and community health leaders regarding opinions on effective 
toolkits (Davis et al., 2017).  Fifty six percent of the sample included PCPs.  Themes of the study 
included that toolkits should be easy to apply and tailor to specific situations and have a “quick 
start guide” (p. 5).  They should also have a table of contents or index.  Two other studies 
conducted systematic reviews of toolkits to illustrate overall effectiveness regarding toolkits. 
Barac et al. (2014) reviewed 83 toolkits (84% were healthcare related), but found only a little 
over one third reported on effectiveness.  Of those reporting effectiveness, 21 found beneficial 
effects.  A Canadian group led by Yamada et al. (2015) evaluated research on 39 patient and 
provider toolkits and concluded that 26 had too weak of study design methods to draw useful 
conclusions.  Of the remaining 13 toolkits, eight studied the outcomes in a randomized controlled 
manner, and six of these eight toolkits were found to be effective.  
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These first three studies provide important themes. Among them are that toolkits should 
be based in evidence and studied in a formal fashion. Toolkits should also bridge research and 
practice to positively influence health outcomes and help with knowledge sharing and facilitate 
behavior and practice change (Barac et al., 2014).  A last noted theme is that the internet is a 
popular and “fertile” ground for their implementation (Barac et al.).  This was especially 
poignant given that past research has noted that printed educational toolkits for providers are 
often not effective (Giguère et al., 2012).  
Two additional studies provide other insight to this project. Keiffer (2015) noted non-
physician providers found toolkits more attractive if they were easy to use and evidence-based.  
The McDonnell Norms group (2016) findings agree noting that convenience and simplicity were 
most important to adoption of clinical practice guidelines into actual practice.  Both studies 
emphasized the importance of easily retrievable guidelines and this may particularly support the 
usefulness of the internet as a host area for future toolkits. 
Review of selected toolkits. Last, this literature review explored primary research articles 
demonstrating effectiveness of toolkits across a variety of clinical conditions. Eleven articles 
were found and are reviewed here.  The first, a study in North Carolina, used a provider toolkit to 
help pediatric physicians in training (residents) coach 115 parents of children ranging from four 
to twelve years old regarding their children’s obesity and lifestyle behaviors (Perrin et al., 2010).  
The toolkit included a stoplight colored BMI chart to educate parents/patients. It also included a 
physical activity and dietary patterns survey to trigger discussion among the physician and 
parent/patient.   Results showed that up to one-half of patients improved their use of healthy 
lifestyle behaviors by the one month follow up.  A weakness of this study is that data was only 
collected at one and three months post intervention.  Other weaknesses of this study include the 
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exclusion of  non-English speaking parents and a high attrition rate. Only 56% of parents 
completed the three month survey. 
Two studies have examined the usefulness of toolkits in primary care management of 
depression. Starkey, Wiest, & Qaseem  (2016) evaluated the use of an online depression toolkit 
in 18 United States physician-only practices. The study found statistically significant 
improvement in substance abuse screening, alcohol abuse screening, and suicide screening after 
using the toolkit (p<0.001). Additionally, providers relied less heavily on antidepressant 
prescriptions (p<0.05) after using the toolkit. Starkey, Wiest, & Qaseem also used Likert scale 
surveys and found more physicians reported feeling confident with depression management post-
intervention than pre-intervention. Their results are limited in generalizability to this project in 
that although they used an online clinical toolkit, their intervention also incorporated practice 
improvement coaching calls.  A strength of the study, however, is the measurement of patient 
outcomes as part of the evaluation of the toolkit. A second study on primary care toolkits for 
depression was conducted by Menchetti et al. (2013).  Generalizability is also limited from this 
study as it included a dedicated psychiatry consultant as part of its intervention and the project 
was conducted in Italy.  However, like Starkey, Wiest, & Qaseem , Menchetti et al. demonstrated 
statistically significant changes from a toolkit including decreased use of sedatives and hypnotics 
and more appropriate use of antidepressants. Treatment response rates were higher at three and 
six months in the intervention group.  
One of the earliest studies of toolkit effectiveness was completed by Bysziewski et al. in 
2003. In this study, 86 United Kingdom PCPs (physicians-only) used a printed toolkit to help 
discuss driving and dementia with their patients. The toolkit included clinical screening 
questions for safe driving, patient education, and algorithms for use of social resources.  The 
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physicians completed pre-use and post-use surveys and demonstrated a 8.4/10 satisfaction rating 
with the toolkit.  The toolkit was also effective (p<=0.5) for improvement in knowledge after use 
and intention to use in practice.   
Three studies have examined toolkits to improve knowledge gaps and clinical care 
outcomes in patients with diabetes. Evans et al. (2017) used a mixed methods design to evaluate 
the use of the United Kingdom WAKEUP toolkit for pre-diabetes and additionally refined the 
written toolkit over two action research cycles. Results were primarily collected through focus 
groups and both patients (n=10) and PCPs (n=12) were part of the project sample.  The PCP 
sample included five nurses but it was unclear whether the nurses were advanced practice or not. 
The toolkit was effective in helping educate and motivate patients. Ninety percent of patients had 
made changes suggested in the patient education part of the tool-kit and 80% of them could 
recite those changes.  Positive findings were also reported by PCPs in the study.  For example, 
PCPs reported being more clear on the need to schedule follow up for pre-diabetes patients. A 
useful finding of this study is that PCPs felt the toolkit would be better implemented with an 
educational introduction first rather than just delivering the toolkit to participants via postal mail.   
The second study of toolkits for diabetic management was completed by Cavanaugh et al. 
(2009) in the eastern United States.  This study was unique in that it was a randomized trial and 
focused on patient outcomes.  It enrolled 198 patients, 99 in the intervention group and 99 in the 
control.  Those patients in the intervention group received care for diabetes from diabetic 
providers (including nurse practitioners) who used the Diabetes Literacy and Numeracy 
Education Toolkit (DLNET) for three months. The patients in the control group received care 
from diabetic providers who did not use this toolkit. The DLNET toolkit included 24 modules 
that healthcare providers could use and modify for their patients regarding various self-care 
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activities.  Data was collected at baseline, three months (intervention conclusion), and six months 
(three months after intervention conclusion).  Statistically clinical improvement was 
demonstrated in glycohemoglobin A1C levels in the intervention group at three months (p=0.03) 
but not at six months.  While the strength of this study was the addition of patient outcome data, 
a weakness was the short follow up period of six months. 
The last study regarding toolkit use in diabetes was a Canadian intervention by Shah et al. 
(2014). This study showed that the toolkit, which incorporated a clinical guideline synopsis and 
patient education tools, was not effective in addressing two cardiovascular outcomes in diabetic 
patients. The primary outcomes studied were the use of a statin and occurrence of myocardial 
infarction.  After implementation of the toolkit, no statistical difference was observed compared 
to before implementation. The authors speculated that since the high baseline rate of statin use 
was already high, this might account for the study finding.  A follow up qualitative study with 
the 88 primary care providers in this cohort suggested other reasons. These included that the 
toolkit was too long (200 pages), in print form, and sent via postal mail, a more passive approach 
(Parsons et al., 2016).  Strengths of Shah et al.  included data collecting data on 933,789 patients 
and the randomization of physician practices to the intervention and control groups.   
Peptic ulcer disease and fall prevention are two other areas where toolkits have been 
studied for their ability to improve quality of care. Two toolkits have been studied in a 
randomized controlled manner. Dykes et al. (2010) tested the effectiveness of a fall prevention 
toolkit while Majumdar et al. (2005) tested the usefulness of a toolkit to diagnose helicobacter 
pylori infection. The study by Dykes et al. (2010) differs from others in this literature review as 
it is the only study reviewed on inpatient management. The study used control (n=4) and 
intervention (n=4) units and used a toolkit delivered via computer software to evaluate fall risk 
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among 10, 264 patients. The toolkit then designed personalized prevention suggestions. The 
toolkit used a Morse fall score, posters, patient education and fall prevention plans. Although 
there was no significant difference between fall related injuries in the control and intervention 
units, the toolkit significantly reduced the number of falls on the intervention units.  The study by 
Majumdar et al. randomized its primary care practice sample into three settings: high intensity 
intervention (n= 312 patients from 6 practices), low intensity intervention (n=147 patients from 3 
practices) and usual care (n= 122 patients from 5 practices).  The tested toolkit incorporated 
practice guidelines, pre-printed modifiable patient letters, and progress note templates. The 
toolkit was used in both high and low intensity intervention sites, with the high intensity 
intervention clinics also receiving pharmacist reminders, group performance details,  and 
educational sessions. Only the high intensity intervention was found to be effective in improving 
the study outcomes, increased recognition of helicobacter pylori and reducing inappropriate 
proton pump inhibitor use.  Strengths of these two studies are the randomized controlled designs. 
Weaknesses include the lack of generalizability to NAFLD care due to differing chronic 
conditions. 
Knowledge gaps regarding Chronic Kidney Disease (CKD) have also been a target for 
toolkit intervention.  Donald et al. (2016) used an online toolkit to increase adherence to CKD 
clinical practice guidelines and address a previously noted performance gap in Canada.  The 
toolkit was evaluated with a mixed method design.  PCPs liked the format of the online toolkit 
since “everything” was in one place.   Eighty three percent of participants reported the toolkit 
increased their knowledge and confidence. Website analytics also showed that 33% of users 
returned to use the toolkit after the study period.  Participants self-reported improved behavior 
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changes in diagnosis and management of CKD, but this was not statistically evaluated which was 
a weakness of the study. 
Pediatric fracture management is the most recent quality improvement focus to be 
addressed by toolkits.  Camp, Barnes, Damany, and Donnan (2017) designed a study to evaluate 
the use of a web based “fracture pathway” for pediatrics. The toolkit used a clinical pathway and 
algorithm to assist an emergency room in Canada to determine which fractures could be 
managed by primary care instead of orthopedic specialty clinics.  Findings included a decreased 
utilization of resources with radiology use decreasing by 24% with use of the toolkit.  Use of the 
specialty clinic was decreased by 12% and authors considered this important in that it reflected 
less parental time off work. However, the authors admitted an inability to confirm a causal 
relationship, however due to study design.  This is a weakness of this study.   
Literature Summary 
 This literature review was helpful in drawing important conclusions regarding toolkit 
design for this project. First, PCPs under recognize NAFLD and desire education regarding this 
topic.   Second, while no toolkits have been specifically developed for NAFLD, toolkits have 
demonstrated their value in several other clinical problems .  However, they are understudied.  
Therefore, this project’s evaluation of the NAFLD toolkit incorporated inferential statistical 
methods and could be used as a pilot study for future research on the toolkit. Third, the majority 
of toolkits demonstrate usefulness, though one study in this review failed to show significant 
usefulness (Shah et al., 2014) and two studies noted high intensity support of a toolkit by experts 
was needed before outcomes improved (Majumdar et al., 2005; Menchetti et al., 2013). Fourth, 
all studies confirmed the toolkit will need incorporate evidence-based practice and best practice 
in terms of design and be easily accessible. Two last noted concepts were that the use of the 
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toolkit could be strengthened by pairing it with an educational session (Evans et al., 2007; 
Grattagliano et al., 2008) or  pharmacist or other specialist support (Majumdar et al., 2005; 
Menchetti et al., 2013; Starkey, Wiest, & Qaseem, 2016). However, theses type of intervention 
are considered beyond the scope of this project, though they could be considered in future 
scholarship with the toolkit. 
Theoretical frameworks 
The Knowledge to Action conceptual framework (appendix N) was used to guide this 
project’s development, implementation, and evaluation (Graham et al., 2006).  This framework 
includes two cycles: the Knowledge creation cycle and the Application cycle. The Knowledge 
Creation Cycle begins with Knowledge Inquiry followed by Knowledge Synthesis. Last, 
knowledge products and tools are developed.  This first cycle describes the process used in the 
development of the toolkit. Knowledge inquiry and synthesis was conducted through the 
literature review and the toolkit development (knowledge product) was developed. The 
Application, or Action, Cycle is the second cycle in the Knowledge to Action framework.  In this 
cycle, the knowledge is implemented and adapted as needed to the context of various situations.  
The knowledge use is monitored and evaluated and refined in a continual, circular process for 
continued use. This cycle closely described the planned process for the implementation and 
evaluation portion of this project. The toolkit will be launched, feedback will be collected, and 
the toolkit refined. 
Assumptions and Objectives 
 This project was based on two assumptions. First, PCNPs in Missouri experienced the 
same knowledge gaps and desired the same education as those noted in the literature review.   
Second, PCNPs will be open to a toolkit for NAFLD and be willing to use it in clinical practice. 
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 This project was guided by three objectives. The first objective was to improve PCNP 
awareness and knowledge of NAFLD.  Second, the project serves to help PCNPs apply clinical 
guidelines and EBP for care of primary care patients with NAFLD.  Last, this project aims to 
evaluate the usefulness of the NAFLD toolkit in meeting objectives one and two. 
Methodology 
Project design 
 This project was designed as a Doctor of Nurse Practice (DNP) EBP and knowledge 
translation project to improve knowledge gaps and support EBP regarding NAFLD.  The project 
focused on educating PCNPs on the management and diagnosis of NAFLD through an online 
provider toolkit.  The toolkit was designed using toolkit development suggestions noted in the 
AHRQ (2016) guide for toolkit development. Additionally, the toolkit was designed using best 
practices identified in the literature review of this paper. 
Specifically, project design involved three phases.  The first phase involved gathering the 
necessary training on NAFLD to provide foundational knowledge of the disorder. To accomplish 
this, a systematic review of the literature for current knowledge and EBP in diagnosis and 
management of NAFLD was conducted.  Much of this literature was reviewed in the Overview 
of NAFLD section of this paper. Additionally, the project director completed the American 
Association for the Study of Liver Disease (AASLD) Liver Learning, Fundamentals of Liver 
Disease: NAFLD and NASH module.   This learning was  complemented with a 40 hour clinical 
with the University of Kansas Medical Center (KUMC) hepatology NASH clinicians (doctor of 
medicine and adult nurse practitioner) to develop clinical expertise and identify patient 
preferences regarding the condition.  Additionally, a 24 hour clinical was completed with a 
certified obesity medicine physician. Because clinical experience is one of the three feature of 
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EBP, the combination of this didactic and clinical learning was critical for the project director to 
obtain additional background knowledge and clinical experience to develop the online toolkit.   
The second phase of the project involved development and pilot review of the online 
toolkit. The toolkit followed best practices in toolkit design by using toolkit development 
checklists from AHRQ (2016). The online provider toolkit is hosted on a free google website. A 
domain and web address for the toolkit was established at 
https://sites.google.com/view/nafldtoolkit/home  (appendix D). Toolkit topics and content areas 
include diagnosis, epidemiology and pathophysiology, patient education, treatment, and 
bibliography.   Pictures used on the toolkit were selected from creative commons licenses.  
Examples of selected tools that are provided in the tool-kit  are included in appendix E through 
H.   After the toolkit was developed, the toolkit was reviewed by the project director using the 
AHRQ  (2016) checklist for toolkit best practices.  Next, the patient education material was 
reviewed by the project director for literacy. The Suitability Assessment of Materials (SAM) 
checklist as described by Doak, Doak, and Root (1996) assured literacy. The SAM checklist is a 
tool to assure patient education materials are written at a level easy to understand by the lay 
public and focused on health literacy. The Flesh-Kinkead readability scale and Simple Measure 
of Gobbledygook (SMOG) was also calculated on the patient education material and assured the 
material was readable at a fifth grade reading level. This is important as one fifth of United 
States public reads at a fifth grade reading level or below (Doak, Doak, & Root, 1996).   Third, a 
pilot review was conducted.  One family nurse practitioner working with NASH patients assured 
content validity and the patient education material referencing dietary recommendations 
(appendix G) was expertly reviewed by a registered dietician working with NASH patients.  
Last, the toolkit was pilot tested by four doctorly prepared PCNPs in the University of Kansas 
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School of Nursing. Weaknesses and inconsistencies with the AHRQ toolkit development 
guidelines were identified through this review. For example, one pilot reviewer identified that 
the NAFLD acronym was used on the title page without first providing the full title.  The issues 
were addressed and the toolkit was updated. 
 The last phase of this project included toolkit implementation and data collection.  
During this phase, the website was published, participants were invited to use the toolkit 
(Appendix M), and the project director evaluated the toolkit to see if it improved PCP knowledge 
gaps and comfort with NAFLD.  This phase is further discussed in the data collection section of 
this proposal. It is important to note that prior to this last phase the project proposal was 
submitted to the University of Kansas Medical Center (KUMC) Internal Review Board (IRB) 
and was approved as an exempt study (Appendix O). 
Project Sample and selection  
 Convenience sampling is a common method of sampling for quality improvement 
research and was considered appropriate for this project due to the similarities to quality 
improvement (Gray, Grove, & Sutherland, 2017). The planned convenience sample of 10 PCNPs 
was exceeded as 11 PCNPs completed both the pre- and post-survey. Inclusion criteria required 
that PCNPs be working in primary care part-time or full-time. Exclusion criteria included those 
NPs working in specialty care or urgent care and student NPs. An additional nine PCNPs 
meeting inclusion criteria completed the pre-survey in entirety, however, they did not continue 
on through the toolkit review and post-survey completion.  These responses were still beneficial 
as they were combined with the eleven other pre-survey responses to provide a general overview 
of the state of  PCNP knowledge regarding NAFLD (appendix Q, R, & S). 
Data collection 
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Instruments.  The data collection instrument for this project is found in appendix I. The 
instrument was selected in the following manner. Three study authors were contacted for use of 
their survey instrument: Said et al. (2013), Wieland et al. (2013), and Patel et al (2017).  Patel et 
al. (2017) was the only team to respond and provide access to their instrument.  Patel et al. 
previously conducted face and content validity of the instrument as described in their paper, 
however, test-retest reliability was deferred for unclear reasons. Because the survey by Patel et 
al. was developed for use in Australia, the instrument was updated and altered for use in the 
United States with guidance from the project committee director and clinical content experts 
(Melissa Laycock, MSN, FNP & Winston Dunn, M.D., personal communication April 4, 2018).   
Differences can be compared between appendix I (modified for this project) and J (original from 
Patel et al.) and also include the following changes. Question 2 was added to obtain a general 
idea of years of experience among participants. Question 20 (appendix I) was added after 
consultation with committee members. The question was added to assess for change in perceived 
comfort and preparedness regarding NAFLD diagnosis and management. 
 Procedure. The project director (DNP student) managed the data for this project. 
Participants were invited to participate in this project via 1) email invitation to active Association 
of Missouri Nurse Practitioners (AMNP) members 2) invitation posted on the webpage for 
AMNP and the Facebook page for AMNP and 3) email invitation to Nurse Practitioner members 
of the Missouri Nurses Association. This third invite was added after the initial two weeks of the 
data collection failed to produce a satisfactory amount of participants. Approval for this addition 
was separately requested and approved by KUMC IRB. Potential participants were informed via 
the email invitation of their rights as study participants and that completion of the surveys 
implied consent to participate in this project.  Upon entering the website, participants were led 
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through three steps.  First, participants completed the pre-survey. Next, the participants were 
asked to review the toolkit and work through the modules.  Then, participants completed the 
post-survey to assess for change in response.  REDCap was used to conduct the surveys and 
protect anonymity. No identifying information, including email, was collected from participants.  
Data analysis  
The data analysis plan consisted of descriptive and analytic statistics and occurred in two 
phases.  In phase one, all PCNPs completing the pre-toolkit survey (n=20) were analyzed to gain 
an understanding of PCNP knowledge, approaches to care, and perceived comfort regarding 
NAFLD.  As previously discussed this data analysis phase was conducted due to the 
underrepresentation of PCNPs in research exploring knowledge gaps among providers. 
Descriptive statistics were used for all analysis in this phase.  Results can be found in appendix 
Q, R and S and are discussed in the results section.   
           Phase two data analysis was conducted with only the survey responses for those PCNPs 
who completed the pre-toolkit survey, reviewed the toolkit, AND completed the post-toolkit 
survey.  There were 11 participants who met this criteria.  Results of this analysis can be found in 
appendix P, T, U, V,  and W.  The survey tool was subdivided into three components for this 
phase of data analysis. 11 questions (Questions 3-13) assessed general knowledge regarding 
NAFLD and were pooled together and correct answers were added to produce a total score for 
each participant. Scores on the pre-survey were compared with scores on post-survey and the 
Wilcoxin signed-rank test for matched pairs was used to compare pre and post-scores for 
statistical differences. Four questions assessed general demographics of the sample and practice 
patterns/experiences (Question 2, 14,15, 17). Another four questions (16, 18-20) assessed for 
clinical approach behaviors.  Question one was used to verify participants met inclusion criteria 
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and question two was used for demographic data collection.  Participants were asked questions 
3-13, 15-16, and 18-20 both pre- and post-exposure to toolkit.  Questions 14, 17 were only asked 
in pre-survey to obtain general practice information and in retrospect, did not influence this 
project’s findings and could have been deleted. Findings of the data analysis are discussed in the 
results section.   
 For all data, outliers were investigated for possible errors and cases with inconsistencies 
were assessed. Graphic representation of the data is included in the appendices. SPSS was used 
to conduct the inferential statistical analyses and Microsoft Excel was used to conduct 
descriptive statistical analyses.  Analyses were conducted by the project director and checked for 
accuracy and appropriate statistical methods by two statisticians. 
Timeline and Budget 
 The project budget and timeline details can be found in appendix K and L.  The costs for 
the project were minimal due to volunteer hours of the project director and use of free pictures 
for the website via creative commons. 
Results 
  Phase one descriptive data analysis provided a general exploration of PCNPs knowledge 
and approach to NAFLD as well as their comfort level regarding caring for NAFLD (appendices 
Q, R, & S). The range of years of experience of the participants was 1-43 years. Analysis of 
knowledge showed several knowledge gaps in some but not all areas (appendix R). This will be 
further discussed in the discussion section. Practice behaviors analysis (Appendix S) showed that 
while PCNPs knew about some guideline suggested interventions, few of them used them. For 
example, there was a high percentage of participants who knew that use of the NAFLD-FS was 
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recommended for use (question 11e and 13d in appendix R; 65 % and 70 %, respectively), yet 
only 15 %  reported using it in clinical practice (question 16b, appendix S). 
 Phase one data analysis also included a correlational analysis which was conducted to 
see if PCNPs with more years of experience (question 2, appendix I) had higher perceived 
comfort with NAFLD (question 20, Appendix Q).  Findings showed there was no correlation 
between these two variables (R=-0.06, p=.787)   
   Phase two data analysis showed four statistically significant findings (appendix X). First, 
there was statistically significant improvement in overall knowledge scores from pre-survey to 
post-survey (appendix X), Second there were statistically significant changes in report of two 
intended actions, use of the NAFLD-FS and referral to weight loss clinic for management.  Last, 
PCNPs in this sample felt better prepared to take care of patients with NAFLD after using the 
toolkit (p=0.0156). 
Phase two data analysis also allowed for qualitative comments. A summary is provided in 
appendix O. Comments of participants were positive including comments like “very helpful…” 
and “…good information”.  The qualitative data also highlighted the challenges of caring for this 
population.  For example, one participant mentioned “Dietitian consult/Medical Nutrition 
Therapy is not covered by most insurers except for diagnosis of Diabetes or Chronic Kidney 
Disease. We can request consult but it is unlikely that patients will follow through after hearing 
the anticipated price.”  (Appendix P, ID22). Other qualitative findings during conduction of this 
project include that the project director was contacted by a NP from New Jersey for permission 
to use the algorithm in a continuing education talk on NAFLD. The NP found the toolkit website 
through a web search. 
Discussion 
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Completion of this project provides important insights for EBP of NAFLD. Only 35% 
percent of this sample agreed (and none strongly agreed) that they had adequate knowledge to 
take care of patients with NAFLD.  This demonstrates an important education need for PCNPs 
and combined with the objectively observed knowledge gaps from appendix Q,  provides insight 
on the state of knowledge for PCNPs, a population underrepresented in current research. PCNPs 
experienced similar knowledge gaps as those described of their physician counterparts in the 
literature. For example, 65% of this project’s sample were unlikely to refer to hepatology unless 
liver function tests were abnormal.  This mirrored the findings of Patel et al. (2017) and Ratziu et 
al. (2012). Additionally, 65% of this sample underestimated the prevalence of NAFLD in the 
obese population and 45 % underestimated the prevalence in the general population which is 
similar to findings by Patel et al. and Said et al (2013).    
Overall, the project findings provide an objective evaluation of an EBP toolkit for 
NAFLD and demonstrate positive outcomes. Moreover, the description of the process of 
development, implementation, and evaluation of this toolkit can be used by other clinicians to 
conduct similar EBP projects on other chronic care conditions. 
Limitations.  
There are a number of limitations to this project’s results.  First, The small sample size  in 
both phase one and phase two analysis and the non-research design of a DNP project limits the 
generalizability of the results. Type two error is a potential limitation for the phase one 
correlational analysis of years of practice with perceived comfort due to the small sample size. 
Likewise, phase two analysis might suffer from type two error due to the small sample size and 
therefore other small, but significant improvements besides the four identified might have 
occurred.  Another limitation of this project is that the survey used in evaluation was from 
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Australia, yet this project was conducted in the United States. This limitation was mitigated, 
however, by expert review of the survey with small changes made to reflect United States 
practice as discussed in the Instruments section.  An additional limitation is that project 
participants completed the post-survey immediately after reviewing the toolkit and  no 
conclusions can be drawn about the success of the toolkit in maintaining improvement in 
knowledge and actions.  Future evaluation of this toolkit should, therefore, include post-survey 
evaluation a month or more after exposure to the toolkit in a longitudinal manner.  Last, this 
project evaluation did not examine patient outcomes and therefore, no generalizations can be 
made as to whether the toolkit improved patient outcomes, though participants did report 
intentions to use more EBP strategies, such as the NAFLD-FS.  Further, some studies such as 
Lucas et al. (2004) and Adorka et al. (2013) have shown that improved clinical knowledge led to 
better patient care decisions in physicians and this project did demonstrate strong clinical 
knowledge improvement. 
Strengths.  
Despite its limitations, this project has many strengths. First, the project was designed in 
an EBP manner after an exhaustive literature search to determine best practices in toolkit design. 
The project also followed best practices according to the highly respected AHRQ and used 
NAFLD national guidelines to guide content. Additionally, the evaluation section of this project 
provides objective, statistically sound data to the body of knowledge regarding effectiveness of 
toolkits to support EBP. This project also used a previously designed survey tool with previously 
proven content validity.  Finally, this project’s pre-survey allowed exploration of PCNP’s 
baseline knowledge and approach to NAFLD, which is a population scantly represented in 
current literature of NAFLD knowledge gaps.   
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Implications 
In this small sample, the NAFLD toolkit improved PCNPs knowledge, intended actions, 
and perceived preparedness. Results support expanding toolkit use nationwide and with other PC 
professions. Because of the limitations, evaluation of this toolkit should be continued with a 
larger sample and over a longer time frame in a longitudinal manner.  Additionally, evaluation 
could be expanded to collect data on patient outcomes of providers that used the toolkit.  Future 
study of this nature is planned in the project directors future scholarship plan. It is also felt that 
this project can serve as a pilot study for research on the NAFLD toolkit.  Strengths and 
limitations identified during this project can be used to design a strong, large sample research 
study.  A study of this nature is needed as there is some but not overwhelming evidential support 
on the success of toolkits in supporting EBP (and none on a NAFLD toolkit).   
 In conclusion, PCPs experience significant knowledge gaps regarding NAFLD. This 
leads to challenges in early recognition and management of NAFLD. Because NAFLD will 
continue to be a pressing concern over the following years, PCPs need education and support in 
caring for these patients. Provider toolkits are one solution to addressing knowledge gaps and 
providing support to PCPs.  This project used the Knowledge to Action framework, national 
clinical practice guidelines, and AHRQ recommendations to design the NAFLD toolkit to 
support PCNPs in EBP. Early evaluation of the toolkit shows promise of the toolkit in improving 
the quality of primary care provided to patients with NAFLD and presents one viable option for 
PCPs to meet the increasing responsibilities placed on them. 
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Appendix A: Letter of Support 
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Appendix B: AUDIT –C  modified for this project from SAMHSA (2017) 
Patient Name _______________________ Date of Visit ________________ 
 
1. How often do you have a drink containing alcohol? 
a. Never 
b. Monthly or less 
c. 2-4 times a month 
d. 2-3 times a week 
e. 4 or more times a week 
 
2. How many standard drinks containing alcohol do you have on a typical day?  * The picture below 
shows 1 standard drink * 
a. 1 or 2 
b. 3 or 4 
c. 5 or 6 
d. 7 to 9 
e. 10 or more 
 
 
*Picture from National Institutes of Health (2017) 
3. How often do you have six or more drinks on one occasion? 
a.Never 
b. Less than monthly 
c. Monthly 
d. Weekly 
e. Daily or almost daily 
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Appendix C: Algorithm for Diagnosis 
 
1. Hepatitis C antibody, Hepatitis B antibody to rule out hepatitis 
2. ceruloplasmin 
3. ANA, IgG, & Antismooth muscle antibodies to rule out Autoimmune hepatitis 
4. Anti mitochondrial antibody to rule out Primary biliary cholangitis  
5. alpha-1 antitrypsin to rule out alpha-1 antitrypsin deficiency 
6. IgA and tissue transglutaminase antibody to rule out celiac disease 
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Appendix D: Adult NAFLD Toolkit 
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Appendix E: NAFLD-FS Calculation: provider documentation form 
 
patient  _______________________________________ 
 
 
Age: 
AST: 
ALT: 
Platelet: 
Albumin: 
BMI: 
Insulin resistant:   yes/no 
 
 
NAFLD-FS =    _________________ 
 Mark one: 
o Low range    (provide action 1 & 2) 
o Indetermine range    (provide action 1, 2 & 3) 
o High range               (provide action 1, 2 & 3) 
 
 
 
Action:      [] 1. Provided education 
                  [] 2.  Recommended to recheck yearly.              
                  [] 3. referred to hepatology.  Appointment date and time: 
 
 
 
 
If elevated AST/ALT 
 
[] AUDIT-C score ________________ 
                  [] Hepatitis C antibody result ________________              
                  [] Hepatitis B antibody result________________ 
                  [] liver ultrasound result ____________________ 
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Appendix F : NAFLD-FS Calculation: Patient form  
Patient name/number________________________________  Date _____________ 
 
 Non Alcoholic Fatty Liver Disease (NAFLD) is a disease where extra fat is stored in the 
liver. Obese people are especially at risk for this disease. When mild, NAFLD does not cause 
problems, but in some people NAFLD can turn into a more severe type of NAFLD, called Non 
Alcoholic Steatohepatitis (NASH) with advanced fibrosis.  The Non-Alcoholic Fatty Liver 
Disease Fibrosis Score (NAFLD-FS) is a scoring system that is used to help determine if you are 
at risk of this severe type. We calculate the score using the data below. 
 
 Age: 
AST: 
ALT: 
Platelet: 
Albumin: 
BMI: 
Insulin resistant:   yes/no 
 
NAFLD-FS =    _________________ 
  
Your score is: 
o Low range.  Patients with a score in this range have a very low risk for complications 
from NAFLD and it is considered safe to manage and monitor the condition with us.  
Healthy eating and exercise are recommended to help treat NAFLD. The ideal 
timeframe for recalculating the NAFLD-FS is uncertain.  We recommend you have 
this rechecked yearly. 
o Indetermine range. Patients with a score in this range have a risk for complications 
from NAFLD, but the exact risk is hard to determine.  We recommend that you see a 
hepatologist (liver doctor) who can determine your risk for complications from 
NAFLD.  We have set this appointment up for you on _____________ at ________. 
We also will help you learn more about NAFLD and eat healthy and exercise.   
o High range. Patients with a score in this range have the highest risk for complications 
from NAFLD, but we cannot determine if you have complications of NAFLD from 
this calculation alone.  We recommend that you see a hepatologist (liver doctor) who 
can determine your risk for complications from NAFLD.  We have set this 
appointment up for you on _____________ at ________. We also will help you learn 
more about NAFLD and eat healthy and exercise.   
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Appendix G: Patient education examples 
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Appendix H: Diary 
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Appendix I  - Survey from Patel et al. (2017) (edited for this project) 
The highlighted answers are the correct answers 
 
Please mark the appropriate answer for each question. 
More than one answer may be appropriate for some questions. 
 
3. In the United States, the prevalence of NAFLD in the general population is: 
 Less than 5%     Approx. 10%    Approx. 30%    Approx. 50%     Unsure 
4. In the United States, the prevalence of NAFLD in the obese population (BMI >30 kg/m2) is: 
 Less than 10%    Approx. 25%   Approx. 50%   Approx. 70%      Unsure 
5. The following conditions are strongly associated with NAFLD: 
a) Overweight / obesity     True   False   Unsure 
b) Type 2 diabetes      True   False   Unsure 
c) Metabolic syndrome     True   False   Unsure 
d) Chronic obstructive pulmonary disea se   True   False   Unsure 
e) Hypertriglyceridemia     True   False   Unsure 
f) Alcohol consumption     True   False   Unsure 
g) Hypertension      True   False   Unsure 
h) Renal impairment      True   False   Unsure 
 
6. For healthy men and women, the lifetime risk of harm from alcohol-related disease is reduced by 
drinking:  
 ≤ 2 standard drinks per day in men/≤1 standard drinks per day in women   
 Related to number of binge drinking sessions 
 ≤ 4men/≤3 women standard drinks per day  Unsure 
 ≤ 6men/≤5 women standard drinks per day 
7. Isolated (simple) steatosis is associated with:  
a) Liver fibrosis in many cases     True   False   Unsure 
b) Increased incidence of cardiovascular disease  True   False   Unsure 
c) Cirrhosis       True   False   Unsure 
d) Future development of type 2 diabetes   True   False   Unsure 
e) Increased liver-related mortality    True   False   Unsure 
  
8. NASH is associated with: 
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a) Liver fibrosis in many cases     True   False   Unsure 
b) Increased incidence of cardiovascular disease  True   False   Unsure 
c) Cirrhosis       True   False   Unsure 
d) Future development of type 2 diabetes   True   False   Unsure 
e) Increased liver-related mortality    True   False   Unsure 
 
9. A diagnosis of NASH can be made using: 
a) Serum liver enzymes      True   False   Unsure 
b) Liver imaging (ultrasound, CT or MRI)   True   False   Unsure 
c) Liver biopsy       True   False   Unsure 
d) Fibroscan       True   False   Unsure 
 
10. Liver enzymes (ALT and AST) are sufficiently sensitive to detect underlying NAFLD-NASH?       
True   False   Unsure 
11. What tests/scores can help to identify NAFLD patients with advanced fibrosis/cirrhosis:  
a) Liver enzymes (ALT, AST)     True   False   Unsure 
b) Platelet count      True   False   Unsure 
c) Serum albumin      True   False   Unsure 
d) Prothrombin time      True  False   Unsure 
e) NAFLD Fibrosis Score     True   False   Unsure 
f) Fib-4 Score       True   False   Unsure 
g) Abdominal ultrasound     True   False   Unsure 
h) ELF score       True   False   Unsure 
 
12. Current therapeutic management of NAFLD involves: 
a) Specific liver-directed pharmacologic therapy             True   False   Unsure 
b) Weight loss                 True  False   Unsure 
c) Physical exercise                True   False   Unsure 
d) Pharmacologic therapy directed at weight loss            True   False   Unsure 
e) Bariatric surgery                    True  False   Unsure 
f) Medical treatment of concurrent metabolic disorders  True   False   Unsure 
 
13. What tests/scores can help to monitor patients with NAFLD for disease progression:  
a) liver enzymes (ALT, AST)    True   False   Unsure 
b) platelet count      True   False   Unsure 
c) Fibroscan      True   False   Unsure 
d) NAFLD Fibrosis Score    True   False   Unsure 
e) liver ultrasound     True   False   Unsure 
f) ELF test      True   False   Unsure 
 
 
14. In my clinic, the percentage of patients with the following factors is:  
a) Type 2 diabetes     ________% 
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b) Dyslipidaemia or hypertriglyceridaemia  ________% 
c) Hypertension     ________% 
d) Overweight or obesity (BMI > 28-30 kg/m2)  ________% 
e) Alcohol excess     ________% 
 
15. The proportion of my patients that are likely to have NAFLD is:  
 None   ≤ 5%   5-10%   10-20%   20-30%   30-40%  40-50%    >50% 
 
16. In my clinical practice I utilize the following tools to assess my patients with NAFLD: 
a) FibroScan      Yes     No   
b) NAFLD Fibrosis Score    Yes     No   
c) Fib4 Score      Yes     No   
d) Abdominal ultrasound    Yes     No   
e) Liver enzymes     Yes     No   
f) APRI Score      Yes     No   
g) ELF test      Yes     No   
 
17. The number of referrals I make to Hepatology each month for an opinion regarding suspected 
NAFLD-NASH is:  None       1-2      3-5  6-10      11-20  21-30       >30 
 
 
 
 
 
18. If I suspect one of my patients has NAFLD, I would:  
a) Provide information on optimising diet & exercise       Yes    No   
b) Provide management plan involving team approach     Yes    No   
c) Refer to exercise/ physical activity     Yes    No     
d) Refer to weight loss clinic       Yes    No   
e) Refer to dietician       Yes    No     
f) Refer to Gastroenterologist / Hepatologist    Yes    No    
g) Refer to Endocrinologist      Yes    No    
 
19. I am unlikely to refer a patient to Hepatology unless liver function tests are abnormal:    True   
False   
20. I have the needed knowledge regarding NAFLD to diagnose, manage, and refer (when 
necessary) these patients 
Strongly Disagree         Disagree           Neutral          Agree             Strongly Agree 
21. Comments: 
I do not refer many patients to Hepatology for NAFLD / NASH 
because:    The patients do not want referral 
     There is no specific pharmacotherapy available  
     I manage them myself by optimising lifestyle 
     The waiting list is too long 
     I don’t see many patients with NAFLD/NASH 
     I do not think it is necessary 
 
If your 
answer is  
none 
‘None’ or  
‘1-2’ 
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Appendix J: Survey, original from Patel et al. (2017) (unedited) 
Non-Alcoholic Fatty Liver Disease (NAFLD) Survey 
 
Aim: To assess opinions of non-alcoholic fatty liver disease (NAFLD) by General Practitioners. It is 
anticipated that this information will help to guide appropriate referral, approaches to specialist care, 
resource allocation and the development of educational strategies. 
Method: Conduct a cross-sectional survey of ~ one hundred General Practitioners and clinicians via a 
structured questionnaire. By completing the questionnaire your consent to participate is implied.  
Things to know before commencing this survey: 
• We are interested in your honest and genuine responses to a number of issues regarding non-alcoholic 
fatty liver disease. 
• Your responses will not be re-identifiable. 
• This is a survey of current opinions and is not designed to be a test of your knowledge of the literature. 
• This questionnaire should take no more than 5-10 minutes to complete. 
• Please feel free to make comments during the questionnaire (in the margin) or after the questionnaire 
(in the space provided) if you have any concerns or suggestions. 
• A surveyor may be present during your questionnaire to facilitate the process. 
 
Please note: All of your responses will be de-identified immediately and collated with other 
respondents without facility for re-identification. 
 
 
Background Information 
 
  
• Non-alcoholic fatty liver disease (NAFLD) is a condition characterised by excessive fat accumulation in 
the liver (“steatosis”) in the presence of metabolic risk factors and the absence of significant alcohol 
intake, systemic illness or medication use known to cause fatty liver disease. (APASL guidelines 2007).  
• Steatosis may occur in the absence of significant inflammation or fibrosis and is often referred to as 
“simple steatosis”. Non-alcoholic steatohepatitis (NASH) defines a subgroup of NAFLD where steatosis 
is accompanied by liver cell injury and inflammation. 
  
My Practice postcode is:  
 
 
My appointment is:  
 
 
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(e.g. GP , Adv Trainee) 
 
Per week, the average number of different patients I see in clinic is:  
 
Please tick the appropriate answer for each question. 
More than one answer may be appropriate for some questions. 
 
1. In Australia, the prevalence of NAFLD in the general population is: 
 Less than 5%     Approx. 10%    Approx. 30%    Approx. 50%     Unsure 
 
2. In Australia, the prevalence of NAFLD in the obese population (BMI >30 kg/m2) is: 
 Less than 10%    Approx. 25%   Approx. 50%   Approx. 70%      Unsure 
 
3. The proportion of my patients that are likely to have NAFLD is:  
 None   ≤ 5%   5-10%   10-20%   20-30%   30-40%  40-50%    >50%    
 
4. The following conditions are strongly associated with NAFLD: 
i) Overweight / obesity     True   False   Unsure 
j) Type 2 diabetes      True   False   Unsure 
k) Metabolic syndrome     True   False   Unsure 
l) Chronic obstructive airways disease    True   False   Unsure 
m) Hypertriglyceridaemia     True   False   Unsure 
n) Alcohol consumption     True   False   Unsure 
o) Hypertension      True   False   Unsure 
p) Renal impairment      True   False   Unsure 
 
5. For healthy men and women, the lifetime risk of harm from alcohol-related disease is reduced by 
drinking:  
 ≤ 2 standard drinks per day   Related to number of binge drinking sessions 
 ≤ 4 standard drinks per day  Unsure 
 ≤ 6 standard drinks per day 
 
6. Isolated (simple) steatosis is associated with:  
a) Liver fibrosis in many cases     True   False   Unsure 
 
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b) Increased incidence of cardiovascular disease  True   False   Unsure 
c) Cirrhosis       True   False   Unsure 
d) Future development of type 2 diabetes   True   False   Unsure 
e) Increased liver-related mortality    True   False   Unsure 
  
7. NASH is associated with: 
a) Liver fibrosis in many cases     True   False   Unsure 
b) Increased incidence of cardiovascular disease  True   False   Unsure 
c) Cirrhosis       True   False   Unsure 
d) Future development of type 2 diabetes   True   False   Unsure 
e) Increased liver-related mortality    True   False   Unsure 
 
8. A diagnosis of NASH can be made using: 
a) Serum liver enzymes      True   False   Unsure 
b) Liver imaging (ultrasound, CT or MRI)   True   False   Unsure 
c) Liver biopsy       True   False   Unsure 
d) Fibroscan       True   False   Unsure 
 
9. Liver enzymes (ALT and AST) are sufficiently sensitive to detect underlying NAFLD-NASH?       
True   False   Unsure 
10. What tests/scores can help to identify NAFLD patients with advanced fibrosis/cirrhosis:  
i) Liver enzymes (ALT, AST)     True   False   Unsure 
j) Platelet count      True   False   Unsure 
k) Serum albumin      True   False   Unsure 
l) Prothrombin time      True   False   Unsure 
m) NAFLD Fibrosis Score     True   False   Unsure 
n) Fib-4 Score       True   False   Unsure 
o) Abdominal ultrasound     True   False   Unsure 
p) ELF score       True   False   Unsure 
q) Fibroscan       True   False   Unsure 
 
11. Current therapeutic management of NAFLD involves: 
g) Specific liver-directed pharmacologic therapy             True   False   Unsure 
h) Weight loss                 True   False   Unsure 
i) Physical exercise                True   False   Unsure 
j) Pharmacologic therapy directed at weight loss            True   False   Unsure 
k) Bariatric surgery                    True   False   Unsure 
l) Medical treatment of concurrent metabolic disorders  True   False   Unsure 
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12. What tests/scores can help to monitor patients with NAFLD for disease progression:  
g) 6 monthly liver enzymes (ALT, AST)    True   False   Unsure 
h) 6 monthly platelet count      True   False   Unsure 
i) Annual Fibroscan      True   False   Unsure 
j) 6 monthly NAFLD Fibrosis Score and/or Fib-4 Score  True   False   Unsure 
k) Annual liver ultrasound     True   False   Unsure 
l) Annual ELF test      True   False   Unsure 
 
13. In my clinic, the percentage of patients with the following factors is:  
17. Type 2 diabetes     ________% 
18. Dyslipidaemia or hypertriglyceridaemia  ________% 
19. Hypertension     ________% 
20. Overweight or obesity (BMI > 28-30 kg/m2)  ________% 
21. Alcohol excess     ________% 
 
14. In my clinical practice I utilise the following tools to assess my patients with NAFLD: 
h) FibroScan      Yes     No   
i) NAFLD Fibrosis Score    Yes     No   
j) Fib4 Score      Yes     No   
k) Abdominal ultrasound    Yes     No   
l) Liver enzymes     Yes     No   
m) APRI Score      Yes     No   
n) ELF test      Yes     No   
15. The centre in Metro South Heath District that I usually refer to for Hepatology is: 
 Logan Hospital  Princess Alexandra Hospital  QEII Hospital  
 Mater Hospital  Private Hospitals 
16. The number of referrals I make to Hepatology each month for an opinion regarding suspected 
NAFLD-NASH is: 
 None       1-2      3-5  6-10      11-20  21-30       >30 
 
 
 
 
 
 
 
 
 
 
I do not refer many patients to Hepatology for NAFLD / NASH 
because:    The patients do not want referral 
     There is no specific pharmacotherapy available  
     I manage them myself by optimising lifestyle 
     The waiting list is too long 
     I don’t see many patients with NAFLD/NASH 
     I do not think it is necessary 
 
If your 
answer is  
‘None’ or  
‘1-2’ 
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17. If I suspect one of my patients has NAFLD, I would:  
22. Provide information on optimising diet & exercise       Yes    No   
23. Provide GP management plan & Team care arrangements   Yes    No   
24. Refer to exercise physiologist     Yes    No     
25. Refer to weight loss clinic       Yes    No   
26. Refer to dietician       Yes    No     
27. Refer to Gastroenterologist / Hepatologist    Yes    No    
28. Refer to Endocrinologist      Yes    No    
 
18. I am unlikely to refer a patient to Hepatology unless liver function tests are abnormal:    True   
False   
 
 
 
 
 
 
Further information and who to contact 
Clinical contact person     Study Coordinator  
Professor Elizabeth Powell Ms Leigh Horsfall 
Chief Principal Investigator; Hepatologist Clinical Research Coordinator 
Tel +61 7 3443 8015 Tel +61 7 3176 1055 
elizabeth.powell@health.qld.gov.au leigh.horsfall@health.qld.gov.au 
If you have any complaints about any aspect of the project, the way it is being conducted or any questions 
about participating in general, then you may contact the HREC approving this research and HREC 
Executive Officer: 
Human Research Ethics Committee Coordinator, Metro South HHS HREC 
Tel: +61 7 3443 8049   
Patient Liaison Officer – Princess Alexandra Hospital 
 
  
Any comments:  
 
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Appendix K: Project timeline 
 
 
Task Start Date # Days Required 
Develop project proposal 1-Dec 75 
Develop toolkit 17-Jan 45 
Project proposal defense 17-Feb 5 
Obtain IRB approval 17-Feb 60 
Pilot toolkit & revise as needed 1-May 14 
Launch Toolkit; Data Collection 15-May 45 
Analyze Data 30-Jun 60 
Report findings 15-Sep 7 
      
 
  
1/Dec 20/Jan 11/Mar 30/Apr 19/Jun 8/Aug 27/Sep
Develop project proposal
Develop toolkit
Project proposal defense
Obtain IRB approval
Pilot toolkit & revise as needed
Launch Toolkit; Data Collection
Analyze Data
Report findings
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Appendix L: Project Budget 
 
Use of google sites = free website 
Development of website = volunteer hours from project director 
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Appendix M: Letter to participants 
 
Dear Colleague, 
 
As a fellow member of the Association of Missouri Nurse Practitioners, I would like to invite 
you to participate in a project I am conducting as a doctoral student at the University of Kansas 
Medical Center (KUMC) School of Nursing.  
 
Title: An Online Toolkit to Improve Primary Care Nurse Practitioner Awareness of Non-
Alcoholic Fatty Liver disease in Adults  
 
If you choose to participate, we will ask you to take a survey, review an online tool-kit for 
NAFLD and repeat the survey at the end.   
 
There are no personal risks to participating in this study beyond the usual risks associated with 
operating a computer and answering questions about identification and treatment of liver disease. 
Taking part in this project is voluntary and you may choose to start or end participation at any 
time over the six week study period. Therefore, you may leave and come back to the project 
survey/site at a later time. Completing both the surveys will be interpreted as your consent to 
participate in this project. Any data that is collected during your participation in the project 
will be collected anonymously and stored on a secure KUMC server.   
 
The benefit of this study is that you may gain new knowledge on NAFLD and contribute to the 
findings of this study, which will be used to improve toolkits for use in primary care. 
Participation or not will have no impact on you and your relationship with this organization or 
KUMC.  
 
Contact Kelly Casler, project director, at kcasler@kumc.edu  if you have any questions about the 
project or the KUMC Institutional Review Board (IRB) at 3901 Rainbow Blvd., MS 1032, 
Kansas City, KS, 66160, (913) 588-1240, or email humansubjects@kumc.edu.  
 
If you agree to be a participant in the project please visit the toolkit at:   
 
https://sites.google.com/view/nafldtoolkit   
 
 
Kelly Casler, MSN, FNP-BC 
Family Nurse Practitioner 
Doctor of Nursing Practice student 
University of Kansas School of Nursing 
 
Kelly Bosak, PhD, ANP-BC 
Associate Professor  
University of Kansas School of Nursing   
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Appendix N: Knowledge To Action Framework (Graham et al., 2006, p. 11) 
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Appendix O: IRB approval 
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Apppendix P: Phase Two Analysis Qualitative comments. 
(Toolkit participants, n=11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID2. [22 years experience] Dietitian consult/Medical Nutrition Therapy is not covered by most insurers 
except for diagnosis of Diabetes or Chronic Kidney Disease. We can request consult but it is unlikely 
that patients will follow through after hearing the anticipated price.  
ID6. [2 years as NP] very helpful and informative 
ID8. [5 years as NP]It was a little hard to follow - not the best flow of the website to try to read things 
in the boxes.  But it contained good informations 
ID11. [“almost 4” years as NP] I have a large Hispanic population in my practice even as young as age 
14-15 that have elevated liver enzymes and upon sonogram show fatty liver. I appreciate this activity. 
Thank you. 
ID21. [1 year as NP] Great presentation and I hope to use this as a reminder in the future as well as for 
patient education.  
ID24. [5 years as NP] Thank you for the useful information. 
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Appendix Q: Phase One analysis Question 20 analysis  
(Participants only responding to pre-survey, n=20) 
 
 
 
 
 
  
Strongly 
Disagree
20% (n=4)
Disagree
25% (n=5)
Neutral
20% (n=4)
Agree
35% (n=7)
Strongly Agree
0%
I HAVE THE NEEDED KNOWLEDGE REGARDING NAFLD TO 
DIAGNOSE, MANAGE, AND REFER THESE PATIENTS (N=20)
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Appendix R: Analysis Group One - Knowledge Questions 
Highlighted cells are those questions where less than 60% answered correctly 
Question 
n answering 
correct (out 
of 20) 
Percent 
answering 
correct 
3 In the United States, the prevalence of NAFLD in the general population is: 6 0.3 
4 In the United States the prevalence of NAFLD in the OBESE population (BMI>30) is: 5 0.25 
5 5.The following conditions are strongly associated with NAFLD   
5a Overweight/obesity 19 0.95 
5b T2DM 19 0.95 
5c Metabolic syndrome 18 0.9 
5d COPD 13 0.65 
5e Hypertriglyceridemia 17 0.85 
5f Alcohol consumption 11 0.55 
5g HTN 12 0.6 
5h Renal Impairment 13 0.65 
6 
For health men and women, the lifetime risk of harm from alcohol-related disease is 
reduced by drinking < 2 standard drinks per day in men, < 1 standard drink per day in 
women. 15 0.75 
7 Isolated (simple)steatosis, or NAFL) is associated with:   
7a liver fibrosis  4 0.2 
7b increased incidence of CVD 4 0.2 
7c cirrhosis 4 0.2 
7d future T2DM 14 0.7 
7e increased liver mortality 4 0.2 
8 NASH is associated with:   
8a liver fibrosis  17 0.85 
8b increased incidence of CVD 15 0.75 
8c cirrhosis 18 0.9 
8d future T2DM 16 0.80 
8e increased liver mortality 19 0.95 
9 A diagnosis of NASH can be made using    
9a serum liver enzymes 12 0.6 
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9b liver imaging(ultrasounds, CT< or MRI) 7 0.35 
9c liver biopsy 19 0.95 
9d Fibroscan 6 0.3 
10 Liver enzymes are sufficiently sensitive to detect underlying NAFLD/NASH 17 0.85 
11 
What tests/scores can help to identify NAFLD patients with advanced 
fibrosis/cirrhosis:     
11a Liver enzymes 14 0.7 
11b platelet count 12 0.6 
11c albumin 12 0.6 
11d Prothrombin time 11 0.55 
11e NAFLDFS 13 0.65 
11f Fib-4 score 7 0.35 
11g Abdominal US 15 0.75 
11h ELF score 7 0.35 
12 Current therapeutic management of NAFLD involves:     
12a specific liver-directed pharm 6 0.30 
12b weight loss 20 1 
12c physical exercise 18 0.9 
12d pharm therapy directed at wt loss 10 0.5 
12e bariatric surgery 10 0.5 
12f treatment of concurrent metabolic disorders 19 0.95 
13 What tests/scores can help to monitor patients with NAFLD for disease progression    
13a Liver enzymes 15 0.75 
13b platelet count 9 0.45 
13c fibroscan 9 0.45 
13d NAFLDFS 14 0.7 
13e Abdominal US 16 0.8 
13f ELF score 8 0.4 
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Appendix S: Analysis Group One. -Clinical behavior questions. 
Highlighted is less than 60% selecting they used 
 
Question 
n 
answering 
true/yes 
(out of 
20) percent 
16 
In my clinical practice I utlize the following tools to assess/monitor my 
patients with NAFLD 
 
 
16a Fibroscan 1 0.05 
16b NAFLD-FS 3 0.15 
16c Fib4 2 0.1 
16d Abd ultrasound 16 0.8 
16e liver enzymes 20 1.0 
16f APRI 3 0.15 
16g ELF test 2 0.1 
18 If I suspect one of my patients has NAFLD, I would   n/a 
18a Provide info on diet & exercise 19 0.95 
18b provide mngmt plan involving team approach 14 0.7 
18c refer to exercise/physical activity 18 0.9 
18d refer to wt loss clinic 8 0.4 
18e refer to dietician 14 0.7 
18f refer to gastroenterologist/hepatologist 15 0.75 
18g refer to endocrinologist 4 0.2 
19 
I am unlikely to refer a patient to hepatology unless liver function tests 
are abnormal (correct answer is false) 7 0.35 
 
 
  
                                                                                             85 
 
Appendix T: Phase Two Analysis  
Change in response on question 20 from pre-survey to post-survey 
 
 
  
  
2
5
1
3
00 0
3
7
1
0
2
4
6
8
Strongly
Disagree
Disagree Neutral Agree Strongly Agree
N
u
m
b
er
I have the needed knowledge regarding NAFLD to 
diagnose, manage, and refer these patients.
Pre/Post toolkit comparison (n=11) (p=0.007)
Pre-toolkit Post-toolkit
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Appendix U: General Knowledge Scores – Pre-Post comparisons 
 
Pre- 
survey 
score 
Post-
survey 
score 
Difference 
pre-post 
 
32 40 8  
16 39 23  
18 36 18  
24 32 8  
26 34 8  
34 34 0  
38 38 0  
32 38 6  
28 37 9  
15 33 18  
39 36 -3 
Mean 27.45455 36.09091 8.636364 
Median 28 36 8 
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Appendix V: Question 16b 
In my clinical practice I utlize the following tools to assess/monitor my patients 
with NAFLD: NAFLD-FS 
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Appendix W: Question 18d 
In my clinical practice I utlize the following tools to assess/monitor my patients 
with NAFLD: NAFLD-FS  
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Appendix X: Overall summary 
Knowledge Questions 
Pre-survey 
n=11 
post-
survey 
n=11 Z* P-value 
Total score         
Median score 28.0 36.0 
2.558 0.011* 
Mean score 27.45 36.09 
*wilcoxon matched pairs signed-rank 
Actions/Behavior questions   
Pre-
survey 
n=11 
Post-
survey 
n=11 Z* P-value 
Number reporting use/will use NAFLD-FS to 
assess/monitor 1 8 2.646 0.008* 
Number reporting use/will use wt loss clinic 
referral for mngmt 2 9 2.646 0.008* 
*wilcoxon matched pairs signed-rank 
 
